Literature DB >> 11096747

Wilson's Disease.

.   

Abstract

Appropriate anticopper therapy for Wilson's disease is the critical element in halting progression of the disease and allowing patient recovery. Selection of the drug or drugs to use for a particular patient depends on the stage of the disease (ie, initial acutely ill patient versus chronic maintenance patient) and the type of presentation (ie, neurologic/psychiatric versus hepatic). I treat patients initially presenting with hepatic disease with a combination of zinc and trientine, those presenting with neurologic/psychiatric disease with tetrathiomolybdate, and those in the maintenance phase with zinc.

Entities:  

Year:  2000        PMID: 11096747     DOI: 10.1007/s11940-000-0002-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  14 in total

1.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

2.  Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.

Authors:  V Yuzbasiyan-Gurkan; A Grider; T Nostrant; R J Cousins; G J Brewer
Journal:  J Lab Clin Med       Date:  1992-09

3.  Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy.

Authors:  O K Mjolnerod; S A Dommerud; K Rasmussen; S T Gjeruldsen
Journal:  Lancet       Date:  1971-04-03       Impact factor: 79.321

4.  Neonatal abnormalities associated with D-penicillamine treatment during pregnancy.

Authors:  L Solomon; G Abrams; M Dinner; L Berman
Journal:  N Engl J Med       Date:  1977-01-06       Impact factor: 91.245

5.  Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.

Authors:  J M Walshe
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

6.  Wilson's disease: clinical presentation and use of prognostic index.

Authors:  H Nazer; R J Ede; A P Mowat; R Williams
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

7.  Treatment of Wilson's disease with zinc: XV long-term follow-up studies.

Authors:  G J Brewer; R D Dick; V D Johnson; J A Brunberg; K J Kluin; J K Fink
Journal:  J Lab Clin Med       Date:  1998-10

8.  Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.

Authors:  G J Brewer; R D Dick; V Yuzbasiyan-Gurkan; V Johnson; Y Wang
Journal:  J Lab Clin Med       Date:  1994-06

9.  Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.

Authors:  G J Brewer; V Johnson; R D Dick; K J Kluin; J K Fink; J A Brunberg
Journal:  Arch Neurol       Date:  1996-10

10.  Initial therapy of patients with Wilson's disease with tetrathiomolybdate.

Authors:  G J Brewer; R D Dick; V Yuzbasiyan-Gurkin; R Tankanow; A B Young; K J Kluin
Journal:  Arch Neurol       Date:  1991-01
View more
  1 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.